Image

Repeat receptor status testing on any residual disease after neoadjuvant systemic therapy.
No evidence-based source recommendation was identified for this topic, which was considered an important aspect of care. This practice point was developed using an expert consensus process.
Repeat receptor status testing on any residual disease after neoadjuvant systemic therapy.
No evidence-based source recommendation was identified for this topic, which was considered an important aspect of care. This practice point was developed using an expert consensus process.